Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going?

Gut

Volumn 50, Issue 5, 2002, Pages 585-588

  Day, C P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; C PEPTIDE; URSODEOXYCHOLIC ACID;

CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; EXERCISE; FATTY LIVER; HEPATITIS; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIVER FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SYMPTOM; WEIGHT REDUCTION;

FATTY LIVER; HEPATITIS C; HUMANS; INSULIN RESISTANCE; LIVER FUNCTION TESTS; OBESITY; RISK FACTORS;

EID: 0036116213     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.5.585     Document Type: Review

References (36)

1. Profile of an urban hospital-based practice
2. Nonalcoholic statohepatitis: An expanded clinical entity
3. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
4. Non-alcoholic steatohepatitis (NASH): A disease of emerging identity and importance
5. Non-alcoholic steatohepatitis: Another disease of affluence
6. Non-alcoholic fatty liver disease. A feature of the metabolic syndrome
7. Prevalence of overweight and obese children between 1989 and 1998: Population based series of cross sectional studies
8. Non-alcoholic fatty liver disease: Predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese
9. Liver in obesity
10. Non-alcoholic fatty liver disease: A spectrum of clinical and pathological severity
11. The natural history of non-alcoholic fatty liver: A follow up study
12. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
13. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
14. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology
15. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology
16. Liver fibrosis in overweight patients
17. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis
18. Non-alcoholic steatohepatitis: A proposal for grading and staging the histological lesions
19. Steatohepatitis: A tale of two "hits"?
20. Non-alcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
21. Nonalcoholic steatohepatitis in children
22. Metformin reverses fatty liver disease in obese, leptin-deficient mice
23. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects
24. Mitochondrial adaptations to obesity-related oxidant stress
25. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis
26. Mitochondria in steatohepatitis
27. Steatohepatitis, spontaneous peroxisomal proliferation and liver tumours in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisomal proliferator-activated receptor α natural ligand metabolism
28. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
29. Mechanisms of disease: Cytokines in alcoholic and non-alcoholic steatohepatitis
30. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis
31. Non-alcoholic steatohepatitis and cryptogenic cirrhosis within kindreds
32. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes
33. The genetic basis for non-alcoholic and alcoholic steatohepatitis
34. Treatment for non-alcoholic fatty liver: Present and emerging therapies
35. A pilot study of a thiazolinedione, troglitazone, in non-alcoholic steatohepatitis
36. Metformin in non-alcoholic steatohepatitis